S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30
S&P 500   4,410.13
DOW   34,364.50
QQQ   353.30

SI-BONE Stock Forecast, Price & News

+0.60 (+2.99%)
(As of 01/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
373,664 shs
Average Volume
306,320 shs
Market Capitalization
$693.24 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SIBN News and Ratings via Email

Sign-up to receive the latest news and ratings for SI-BONE and its competitors with MarketBeat's FREE daily newsletter.

SI-BONE logo


SI-BONE, Inc. engages in the provision of implantable devices used in the surgical treatment of the sacropelvic anatomy. It offers a proprietary minimally invasive surgical implant system, called iFuse, used to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that often causes severe lower back pain. The company was founded by Mark A. Reiley and Jeffrey W. Dunn on March 18, 2008 and is headquartered in Santa Clara, CA.


SI-BONE, Inc. (NASDAQ:SIBN) Insider Sells $14,652.00 in Stock
January 19, 2022 |  americanbankingnews.com
SI-BONE (NASDAQ:SIBN) Shares Gap Up to $21.82
January 14, 2022 |  americanbankingnews.com
Critical Survey: Pulmonx (NASDAQ:LUNG) versus SI-BONE (NASDAQ:SIBN)
January 14, 2022 |  americanbankingnews.com
SI-BONE (NASDAQ:SIBN) Stock Price Up 4.8%
January 10, 2022 |  americanbankingnews.com
SI-BONE (NASDAQ:SIBN) Given "Buy" Rating at Needham & Company LLC
January 10, 2022 |  americanbankingnews.com
SI-BONE guides Q4 and FY21 revenue above consensus
January 10, 2022 |  seekingalpha.com
SI-BONE (NASDAQ:SIBN) Shares Down 6.3%
January 7, 2022 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Surgical & medical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$73.39 million
Book Value
$5.23 per share


Net Income
$-43.70 million
Pretax Margin




Free Float
Market Cap
$693.24 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.23 out of 5 stars

Medical Sector

362nd out of 1,415 stocks

Surgical & Medical Instruments Industry

42nd out of 130 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

SI-BONE (NASDAQ:SIBN) Frequently Asked Questions

Is SI-BONE a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for SI-BONE in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SI-BONE stock.
View analyst ratings for SI-BONE
or view top-rated stocks.

How has SI-BONE's stock price been impacted by Coronavirus (COVID-19)?

SI-BONE's stock was trading at $15.32 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SIBN stock has increased by 35.1% and is now trading at $20.70.
View which stocks have been most impacted by COVID-19

When is SI-BONE's next earnings date?

SI-BONE is scheduled to release its next quarterly earnings announcement on Monday, March 14th 2022.
View our earnings forecast for SI-BONE

How were SI-BONE's earnings last quarter?

SI-BONE, Inc. (NASDAQ:SIBN) issued its earnings results on Monday, November, 8th. The company reported ($0.48) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.06. The firm earned $22.29 million during the quarter, compared to the consensus estimate of $22.71 million. SI-BONE had a negative trailing twelve-month return on equity of 32.49% and a negative net margin of 58.66%. During the same quarter last year, the company earned ($0.33) EPS.
View SI-BONE's earnings history

What guidance has SI-BONE issued on next quarter's earnings?

SI-BONE updated its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $89 million-$90 million, compared to the consensus revenue estimate of $92.71 million.

What price target have analysts set for SIBN?

6 equities research analysts have issued 1 year target prices for SI-BONE's stock. Their forecasts range from $30.00 to $40.00. On average, they anticipate SI-BONE's share price to reach $34.80 in the next year. This suggests a possible upside of 68.1% from the stock's current price.
View analysts' price targets for SI-BONE
or view top-rated stocks among Wall Street analysts.

Who are SI-BONE's key executives?

SI-BONE's management team includes the following people:

What is Jeffrey Dunn's approval rating as SI-BONE's CEO?

10 employees have rated SI-BONE CEO Jeffrey Dunn on Glassdoor.com. Jeffrey Dunn has an approval rating of 41% among SI-BONE's employees. This puts Jeffrey Dunn in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of SI-BONE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SI-BONE investors own include (HON), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Verizon Communications (VZ), Alibaba Group (BABA), Cisco Systems (CSCO) and CSX (CSX).

When did SI-BONE IPO?

(SIBN) raised $84 million in an IPO on Wednesday, October 17th 2018. The company issued 6,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is SI-BONE's stock symbol?

SI-BONE trades on the NASDAQ under the ticker symbol "SIBN."

Who are SI-BONE's major shareholders?

SI-BONE's stock is owned by a number of institutional and retail investors. Top institutional investors include Diversified Trust Co (0.03%). Company insiders that own SI-BONE stock include Anthony J Recupero, Anthony J Recupero, Gregory K Hinckley, Jeffrey W Dunn, Jeffrey W Dunn, Jeryl L Hilleman, John Gordon Freund, Laura Francis, Michael A Pisetsky, Michael A Pisetsky and Skyline Venture Partners V Lp.
View institutional ownership trends for SI-BONE

Which major investors are buying SI-BONE stock?

SIBN stock was acquired by a variety of institutional investors in the last quarter, including Diversified Trust Co.
View insider buying and selling activity for SI-BONE
or or view top insider-buying stocks.

How do I buy shares of SI-BONE?

Shares of SIBN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SI-BONE's stock price today?

One share of SIBN stock can currently be purchased for approximately $20.70.

How much money does SI-BONE make?

SI-BONE has a market capitalization of $693.24 million and generates $73.39 million in revenue each year. The company earns $-43.70 million in net income (profit) each year or ($1.55) on an earnings per share basis.

How many employees does SI-BONE have?

SI-BONE employs 295 workers across the globe.

What is SI-BONE's official website?

The official website for SI-BONE is www.si-bone.com.

Where are SI-BONE's headquarters?

How can I contact SI-BONE?

SI-BONE's mailing address is 471 EL CAMINO REAL SUITE 101, SANTA CLARA CA, 95050. The company can be reached via phone at (408) 207-0700 or via email at [email protected].

This page was last updated on 1/25/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.